Literature DB >> 33639955

Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors.

Halima Rhazi1,2, Najete Safini3, Karima Mikou4, Meryeme Alhyane3, Khalid Omari Tadlaoui3, Xiangliang Lin5, Nandini P Venkatesan5, Mehdi Elharrak3.   

Abstract

BACKGROUND: Animal vaccination is an important way to stop the spread of diseases causing immense damage to livestock and economic losses and the potential transmission to humans. Therefore effective method for vaccine production using simple and inexpensive bioprocessing solutions is very essential. Conventional culture systems currently in use, tend to be uneconomic in terms of labor and time involved. Besides, they offer a limited surface area for growth of cells. In this study, the CelCradle™-500A was evaluated as an alternative to replace conventional culture systems in use such as Cell factories for the production of viral vaccines against small ruminant morbillivirus (PPR), rift valley fever virus (RVF) and lumpy skin disease virus (LSD).
RESULTS: Two types of cells Vero and primary Lamb Testis cells were used to produce these viruses. The study was done in 2 phases as a) optimization of cell growth and b) virus cultivation. Vero cells could be grown to significantly higher cell densities of 3.04 × 109 using the CelCradle™-500A with a shorter doubling time as compared to 9.45 × 108 cells in Cell factories. This represents a 19 fold increase in cell numbers as compared to seeding vs only 3.7 fold in Cell factories. LT cells achieved modestly higher cell densities of 6.7 × 108 as compared to 6.3 × 108 in Cell factories. The fold change in densities for these cells was 3 fold in the CelCradle™-500A vs 2.5 fold in Cell factories. The titers in the conventional system and the bioreactor were not significantly different. However, the Cell-specific virus yield for rift valley fever virus and lumpy skin disease virus are higher (25 virions/cell for rift valley fever virus, and 21.9 virions/cell for lumpy skin disease virus versus 19.9 virions/cell for rift valley fever virus and 10 virions/cell for lumpy skin disease virus).
CONCLUSIONS: This work represents a novel study for primary lamb testis cell culture in CellCradle™-500A bioreactors. In addition, on account of the high cell densities obtained and the linear scalability the titers could be further optimized using other culture process such us perfusion.

Entities:  

Keywords:  CelCradle™ -500A; LSD virus; LT cells; PPR virus; RVF virus; Vero cells

Mesh:

Year:  2021        PMID: 33639955      PMCID: PMC7913422          DOI: 10.1186/s12917-021-02801-4

Source DB:  PubMed          Journal:  BMC Vet Res        ISSN: 1746-6148            Impact factor:   2.741


  22 in total

1.  A novel oscillating bioreactor BelloCell: implications for insect cell culture and recombinant protein production.

Authors:  Jen-Te Lu; Yao-Chi Chung; Zun-Ren Chan; Yu-Chen Hu
Journal:  Biotechnol Lett       Date:  2005-08       Impact factor: 2.461

2.  A novel control scheme for inducing angiostatin-human IgG fusion protein production using recombinant CHO cells in a oscillating bioreactor.

Authors:  Ing-Kae Wang; Sing-Ying Hsieh; King-Ming Chang; Yu-Chi Wang; Andy Chu; Shyh-Yu Shaw; Jung-Jung Ou; Lewis Ho
Journal:  J Biotechnol       Date:  2005-09-12       Impact factor: 3.307

3.  A microcarrier-based cultivation system for expansion of primary mesenchymal stem cells.

Authors:  Simone Frauenschuh; Elisabeth Reichmann; Yvonne Ibold; Peter M Goetz; Michael Sittinger; Jochen Ringe
Journal:  Biotechnol Prog       Date:  2007 Jan-Feb

4.  Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor.

Authors:  Hiroko Toriniwa; Tomoyoshi Komiya
Journal:  Biologicals       Date:  2007-04-02       Impact factor: 1.856

5.  Cultivation of HEK 293 cell line and production of a member of the superfamily of G-protein coupled receptors for drug discovery applications using a highly efficient novel bioreactor.

Authors:  Lewis Ho; Cynthia L Greene; Anne W Schmidt; Liang H Huang
Journal:  Cytotechnology       Date:  2004-07       Impact factor: 2.058

6.  Process intensification for Peste des Petites Ruminants Virus vaccine production.

Authors:  Marcos Sousa; Christel Fenge; Jens Rupprecht; Alexander Tappe; Gerhard Greller; Paula Alves; Manuel Carrondo; António Roldão
Journal:  Vaccine       Date:  2019-08-08       Impact factor: 3.641

7.  Preparation of human rabies vaccine in VERO cell culture using a microcarrier system.

Authors:  R Z Mendonça; L M Ioshimoto; R M Mendonça; M De-Franco; E J Valentini; W Beçak; I Raw; C A Pereira
Journal:  Braz J Med Biol Res       Date:  1993-12       Impact factor: 2.590

8.  In vitro expansion and differentiation of rat pancreatic duct-derived stem cells into insulin secreting cells using a dynamicthree-dimensional cell culture system.

Authors:  X C Chen; H Liu; H Li; Y Cheng; L Yang; Y F Liu
Journal:  Genet Mol Res       Date:  2016-06-27

9.  Evaluation of novel disposable bioreactors on pandemic influenza virus production.

Authors:  Chia-Chun Lai; Tsai-Chuan Weng; Yu-Fen Tseng; Jen-Ron Chiang; Min-Shi Lee; Alan Yung-Chih Hu
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

10.  Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels.

Authors:  S Daouam; F Ghzal; Y Naouli; K O Tadlaoui; M M Ennaji; C Oura; M El Harrak
Journal:  BMC Vet Res       Date:  2016-07-26       Impact factor: 2.741

View more
  1 in total

1.  High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor.

Authors:  Anna Offersgaard; Carlos Rene Duarte Hernandez; Anne Finne Pihl; Nandini Prabhakar Venkatesan; Henrik Krarup; Xiangliang Lin; Udo Reichl; Jens Bukh; Yvonne Genzel; Judith Margarete Gottwein
Journal:  Vaccines (Basel)       Date:  2022-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.